MX2016011862A - Inhibidores de c5a para el tratamiento de la neumonia viral. - Google Patents
Inhibidores de c5a para el tratamiento de la neumonia viral.Info
- Publication number
- MX2016011862A MX2016011862A MX2016011862A MX2016011862A MX2016011862A MX 2016011862 A MX2016011862 A MX 2016011862A MX 2016011862 A MX2016011862 A MX 2016011862A MX 2016011862 A MX2016011862 A MX 2016011862A MX 2016011862 A MX2016011862 A MX 2016011862A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- pneumonia
- inhibitors
- viral pneumonia
- relates
- Prior art date
Links
- 206010035737 Pneumonia viral Diseases 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 208000009421 viral pneumonia Diseases 0.000 title abstract 4
- 206010035664 Pneumonia Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a inhibidores de C5a para uso en el tratamiento de la neumonía, especialmente de la neumonía viral. La invención también se refiere al uso de inhibidores de C5a en la preparación de una composición farmacéutica para el tratamiento de la neumonía, especialmente de la neumonía viral. Los inventores se refieren además a métodos para el tratamiento de la neumonía, especialmente de la neumonía viral, que comprenden la etapa de administrar una cantidad terapéutica de un inhibidor de C5a a un sujeto en necesidad del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14160947 | 2014-03-20 | ||
| PCT/EP2015/055947 WO2015140304A1 (en) | 2014-03-20 | 2015-03-20 | Inhibitors of c5a for the treatment of viral pneumonia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016011862A true MX2016011862A (es) | 2016-12-05 |
Family
ID=50342223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016011862A MX2016011862A (es) | 2014-03-20 | 2015-03-20 | Inhibidores de c5a para el tratamiento de la neumonia viral. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10227397B2 (es) |
| EP (1) | EP3119802B1 (es) |
| JP (2) | JP6718379B2 (es) |
| KR (1) | KR20160127042A (es) |
| CN (2) | CN106132982A (es) |
| AU (1) | AU2015233380A1 (es) |
| BR (1) | BR112016021629A2 (es) |
| CA (1) | CA2940319A1 (es) |
| CL (1) | CL2016002255A1 (es) |
| EA (1) | EA201691481A1 (es) |
| IL (1) | IL247364A0 (es) |
| MX (1) | MX2016011862A (es) |
| PH (1) | PH12016501830A1 (es) |
| SG (1) | SG11201607740TA (es) |
| WO (1) | WO2015140304A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106132982A (zh) | 2014-03-20 | 2016-11-16 | 因弗拉克斯有限责任公司 | 用于治疗病毒性肺炎的C5a抑制剂 |
| MA39763A (fr) | 2014-03-20 | 2017-01-25 | Samumed Llc | Indazole-3-carboxamides 5-substitués, et préparation et utilisation de ceux-ci |
| AP2016009612A0 (en) | 2014-06-12 | 2016-12-31 | Ra Pharmaceuticals Inc | Modulation of complement activity |
| HRP20211824T1 (hr) | 2015-01-28 | 2022-03-04 | Ra Pharmaceuticals, Inc. | Modulatori aktivnosti komplementa |
| HUE061759T2 (hu) | 2015-12-16 | 2023-08-28 | Ra Pharmaceuticals Inc | Komplement aktivitás modulátorai |
| CN109310760A (zh) | 2016-06-07 | 2019-02-05 | 诺华股份有限公司 | 抗c5抗体给药方案 |
| MY196006A (en) | 2016-06-14 | 2023-03-06 | Regeneron Pharma | Anti-C5 Antibodies and Uses Thereof |
| BR112019011053A2 (pt) | 2016-12-07 | 2019-10-15 | Ra Pharmaceuticals Inc | moduladores da atividade do complemento |
| US10376595B2 (en) * | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| IL261809B2 (en) * | 2017-04-03 | 2024-04-01 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5A activity |
| CA3066689C (en) * | 2017-06-23 | 2024-01-16 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of c5a activity |
| KR20200098528A (ko) | 2017-12-13 | 2020-08-20 | 리제너론 파아마슈티컬스, 인크. | 항-c5 항체 조합물 및 이의 용도 |
| MX2022001896A (es) | 2019-08-16 | 2022-06-02 | Regeneron Pharma | Formulaciones anti-c5 de alta concentracion. |
| TWI834025B (zh) * | 2020-03-06 | 2024-03-01 | 美商奥默羅斯公司 | 用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法 |
| EP4126222A1 (en) * | 2020-03-27 | 2023-02-08 | InflaRx GmbH | Inhibitors of c5a for the treatment of corona virus infection |
| WO2021211940A1 (en) * | 2020-04-16 | 2021-10-21 | Assistance Publique, Hopitaux De Paris | Methods for treating a complement mediated disorder caused by viruses |
| TW202208427A (zh) * | 2020-05-06 | 2022-03-01 | 德商因夫萊亞斯有限公司 | 人源化抗ｃ５ａ抗體 |
| CN118251491A (zh) | 2021-10-28 | 2024-06-25 | 瑞泽恩制药公司 | 用于敲除C5的CRISPR/Cas相关方法及组合物 |
| US12180274B2 (en) | 2023-05-26 | 2024-12-31 | Inflarx Gmbh | Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100391537C (zh) * | 2001-08-17 | 2008-06-04 | 建南德克公司 | 结合至c5和c5a但不阻止c5b形成的补体途径抑制剂 |
| CN1642983A (zh) * | 2002-01-25 | 2005-07-20 | G2治疗有限公司 | 抗C5aR抗体及其应用 |
| EP2327725A1 (en) * | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
| AU2011204483B2 (en) * | 2010-01-08 | 2016-02-11 | Volution Immuno Pharmaceuticals Sa | EV576 for use in the treatment of viral infections of the respiratory tract |
| EP2563813B1 (en) | 2010-04-30 | 2015-08-26 | Alexion Pharmaceuticals, Inc. | Anti-c5a antibodies and methods for using the antibodies |
| KR101849738B1 (ko) * | 2010-06-17 | 2018-04-17 | 트렐리스 바이오싸이언스 인코포레이티드 | 수동 인플루엔자 면역에 유용한 항체 |
| CN106132982A (zh) | 2014-03-20 | 2016-11-16 | 因弗拉克斯有限责任公司 | 用于治疗病毒性肺炎的C5a抑制剂 |
-
2015
- 2015-03-20 CN CN201580014552.0A patent/CN106132982A/zh active Pending
- 2015-03-20 KR KR1020167025906A patent/KR20160127042A/ko not_active Ceased
- 2015-03-20 EP EP15711177.4A patent/EP3119802B1/en active Active
- 2015-03-20 MX MX2016011862A patent/MX2016011862A/es unknown
- 2015-03-20 SG SG11201607740TA patent/SG11201607740TA/en unknown
- 2015-03-20 BR BR112016021629A patent/BR112016021629A2/pt not_active Application Discontinuation
- 2015-03-20 WO PCT/EP2015/055947 patent/WO2015140304A1/en not_active Ceased
- 2015-03-20 AU AU2015233380A patent/AU2015233380A1/en not_active Abandoned
- 2015-03-20 CN CN202310453303.8A patent/CN116785426A/zh active Pending
- 2015-03-20 US US15/127,676 patent/US10227397B2/en active Active
- 2015-03-20 CA CA2940319A patent/CA2940319A1/en not_active Abandoned
- 2015-03-20 EA EA201691481A patent/EA201691481A1/ru unknown
- 2015-03-20 JP JP2016558056A patent/JP6718379B2/ja active Active
-
2016
- 2016-08-18 IL IL247364A patent/IL247364A0/en unknown
- 2016-09-06 CL CL2016002255A patent/CL2016002255A1/es unknown
- 2016-09-19 PH PH12016501830A patent/PH12016501830A1/en unknown
-
2019
- 2019-01-24 US US16/256,100 patent/US10858421B2/en active Active
-
2020
- 2020-04-16 JP JP2020073194A patent/JP7041708B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017514791A (ja) | 2017-06-08 |
| EA201691481A1 (ru) | 2017-02-28 |
| CN106132982A (zh) | 2016-11-16 |
| BR112016021629A2 (pt) | 2018-07-10 |
| KR20160127042A (ko) | 2016-11-02 |
| PH12016501830A1 (en) | 2016-11-21 |
| JP2020125324A (ja) | 2020-08-20 |
| JP7041708B2 (ja) | 2022-03-24 |
| US10227397B2 (en) | 2019-03-12 |
| CA2940319A1 (en) | 2015-09-24 |
| US20170137499A1 (en) | 2017-05-18 |
| EP3119802A1 (en) | 2017-01-25 |
| SG11201607740TA (en) | 2016-10-28 |
| CL2016002255A1 (es) | 2017-08-25 |
| JP6718379B2 (ja) | 2020-07-08 |
| IL247364A0 (en) | 2016-11-30 |
| US10858421B2 (en) | 2020-12-08 |
| US20190202900A1 (en) | 2019-07-04 |
| CN116785426A (zh) | 2023-09-22 |
| AU2015233380A1 (en) | 2016-09-08 |
| EP3119802B1 (en) | 2019-12-04 |
| WO2015140304A1 (en) | 2015-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501830A1 (en) | Inhibitors of c5a for the treatment of viral pneumonia | |
| ZA202004557B (en) | Modulatory polynucleotides | |
| TW201613901A (en) | New compounds | |
| MY187540A (en) | Compounds active towards bromodomains | |
| MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
| PH12016500094A1 (en) | Autotaxin inhibitors | |
| MX2015016741A (es) | Inhibidores de pi3 cinasa delta y gama selectivos duales. | |
| PH12016502291A1 (en) | Indolizine derivatives as phosphoinositide 3-kinases inhibitors | |
| MX2017002816A (es) | Derivados de pirazolopiridina y su uso en terapia. | |
| MD20170048A2 (ro) | Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia | |
| MX2017004808A (es) | Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple. | |
| MY199091A (en) | Therapeutic compounds | |
| IN2014MU00303A (es) | ||
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| MX2017007188A (es) | Compuesto antimicotico. | |
| PH12017500089A1 (en) | Aldosterone synthase inhibitors | |
| PH12016502530A1 (en) | Pharmaceutical compositions comprising dgla and use of same | |
| PH12016501686A1 (en) | Pharmaceutical compositions of sitagliptin | |
| MX2020009444A (es) | Composicion farmaceutica oral de isotretinoina con dosis baja y su proceso de preparacion. | |
| PH12017500348B1 (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
| PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| IN2014MU00916A (es) | ||
| IN2014CH00840A (es) | ||
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| IN2013MU03428A (es) |